瑞巴派特保留灌肠治疗溃疡性结肠炎临床疗效

Therapeutic Effect of Rebamipide Enema Retention Therapy on Ulcerative Colitis

目的:观察瑞巴派特保留灌肠治疗溃疡性结肠炎(UC)的临床疗效及安全性。方法:随机将128例UC患者分成A、B两组,两组均给与奥沙拉嗪常规治疗,A组患者用瑞巴派特保留灌肠,B组用复方锡类散液保留灌肠治疗。结果:A组患者有效率(93.75%)明显高于B组(81.25%)(P<0.05),未见明显不良反应。结论:瑞巴派特保留灌肠能有效保护UC患者结肠黏膜并促进溃疡愈合,不良反应少,联合奥沙拉嗪能有效治疗溃疡性结肠炎。

Objective： To evaluate the clinical therapeutic effect and security of rebamipide enema retention therapy on treatment of ulcerative colitis. Method： One hundred and twenty-eight patients of ulcerative colitis were randomly divided into A and B group. Both groups were treated by olsalazine. A group was given enemaed retention therapy by rebamipide, B group was given enemaed reten- tion therapy by compound Xileisan liquid. Result： The efficacy rate of A group（93.75% ） was obviously higher than that of B group （81.25%） （P 〈 0.05 ）, No obvious adverse reaction was discovered. Conclusion： Rebamipide enema retention therapy can effectively protect the colonic mucosa, improve colonic ulcer healing with fewer adverse reactions. It combined with olsalazine may effectively treat of ulcerative colitis.